EMA Revises Access Policy To Clarify Which Corporate Records Are Public
Executive Summary
The European Medicines Agency is inviting feedback on changes to its policy on access to documents to clarify that it also covers the agency’s corporate documents.
You may also be interested in...
Pharma Opposes 'Harmful' Changes To EMA’s Access To Documents Policy
The EU pharmaceutical industry has concerns about the European Medicines Agency’s proposal to grant extended access to documents on orphan designations and pediatric investigation plans under its revised access to documents policy. The changes would discourage innovation and lead to inadvertent disclosure of commercially sensitive data, companies claim.
EMA Appeals Interim EU Court Orders Preventing Access To Documents
The European Medicines Agency is looking for a clear indication from the EU courts on whether its approach to transparency – as defined in its access to documents policy – is correct.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.